• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 30, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Circular RNAs linked to poorer survival in cholangiocarcinoma, meta-analysis finds

by
October 29, 2026
in Cancer, Health
Reading Time: 3 mins read
0
Circular RNAs linked to poorer survival in cholangiocarcinoma, meta-analysis finds

Circular RNAs linked to poorer survival in cholangiocarcinoma, meta-analysis finds

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

High levels of oncogenic circular RNAs are associated with markedly poorer overall survival in patients with cholangiocarcinoma, while high levels of tumor-suppressive circular RNAs are linked to better outcomes, according to a systematic review and meta-analysis published in BMC Cancer.

They are aberrantly expressed in various human cancers and can regulate tumor cell proliferation, invasion, and metastasis through multiple mechanisms. Until now, however, most studies of circRNAs in cholangiocarcinoma have been single-center efforts with small sample sizes, and no systematic quantitative evaluation of the field existed.

The new analysis, registered on PROSPERO (CRD420261352256), was carried out by two researchers who independently searched the Web of Science and PubMed databases, with a final search date of September 28, 2025. Studies were eligible if they used a cohort or case-control design, detected circRNAs by RT-qPCR, and reported clinicopathological data. Reviews, studies with duplicate data, non-human research, and publications in languages other than English or Chinese were excluded. Risk of bias was assessed with the Newcastle-Ottawa Scale, and all primary meta-analyses used a random-effects model in StataSE 12.0.

The included studies came from China and from a multinational cohort spanning France and Spain, and all used qRT-PCR to measure circRNA expression. High- and low-expression groups were defined using various cut-off criteria, including the median, the mean, X-tile, and the Youden index derived from ROC analysis.

When the pooled results were analyzed, high expression of oncogenic circRNAs was associated with poorer overall survival, with a hazard ratio of 2.27 (95% CI: 2.02–2.55). Conversely, high expression of tumor-suppressive circRNAs was linked to a favorable prognosis, with a hazard ratio of 0.53 (95% CI: 0.47–0.60). The authors note that these pooled hazard ratios are estimates across heterogeneous studies rather than predictions for individual patients.

Beyond survival, the meta-analysis examined whether circRNA expression correlated with clinicopathological features. Expression was not significantly associated with age, CA19-9 levels, or gender, but it was significantly associated with tumor differentiation (OR = 1.72), lymph node metastasis (OR = 3.43), and TNM stage (OR = 2.91). Taken together, the authors write, these findings indicate that dysregulated circRNA expression is closely associated with malignant progression of cholangiocarcinoma.

The study’s conclusion is deliberately cautious. The authors state that circRNAs might represent candidate prognostic markers requiring further validation, not established clinical tools. They also flag several limitations of the evidence base: a geographic bias, since most included studies were conducted in China; heterogeneity in the cut-off values used to define high versus low expression; and potential publication bias. Large-scale, well-designed studies are still needed, they conclude, to verify the actual clinical utility of these molecules.

For researchers, the pooled hazard ratios offer a quantitative benchmark for a biomarker class that has so far been described study by study. For patients, the message is more restrained: the association between circRNA expression and survival in cholangiocarcinoma is now supported by a systematic synthesis of the available literature, but whether measuring these molecules can improve diagnosis, risk stratification, or treatment decisions in routine care remains untested and will require prospective validation in larger and more geographically diverse cohorts.

Subject of Research: Prognostic and clinicopathological significance of circular RNA expression in cholangiocarcinoma

Article Title: Prognostic and clinicopathological significance of circular RNA expression in cholangiocarcinoma: a systematic review and meta-analysis

Article References: Yu, Y., Shen, L., Ni, T., Ding, L., Zhang, X., & Fan, K. (2026). Prognostic and clinicopathological significance of circular RNA expression in cholangiocarcinoma: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17232-3

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17232-3

Keywords: cholangiocarcinoma, circular RNA, circRNA, meta-analysis, systematic review, prognosis, biomarkers, overall survival, lymph node metastasis, RT-qPCR, BMC Cancer, Prognostic

News Source: Nathaniel Bowman. (October 29, 2026). Circular RNAs linked to poorer survival in cholangiocarcinoma, meta-analysis finds. Scienmag.

Tags: biomarkersBMC CancercholangiocarcinomacircRNAcircular RNAlymph node metastasisMeta-analysisoverall survivalprognosisprognosticRT-qPCRsystematic review
Share12Tweet7Share2ShareShareShare1

Related Posts

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

October 30, 2026
Most Ethiopian HIV patients on dolutegravir therapy show good knowledge, survey finds

Most Ethiopian HIV patients on dolutegravir therapy show good knowledge, survey finds

October 30, 2026

Serum and urine protein biomarkers may sharpen prostate cancer detection beyond PSA

October 30, 2026

One gene locus flags atrial fibrillation risk after major surgery, UK Biobank study finds

October 30, 2026

POPULAR NEWS

  • Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    29 shares
    Share 12 Tweet 7
  • Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

    29 shares
    Share 12 Tweet 7
  • ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

    29 shares
    Share 12 Tweet 7
  • Systematic review maps sustainability tensions in offshore wind development

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.